NEW YORK (GenomeWeb) – Amarantus Bioscience said today that it has reacquired the rights to three neurology diagnostic tests from Avant Diagnostics.

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro. Under the terms of the deal, Amarantus will cancel all liabilities, totaling about $722,000, owed by Avant. Amarantus will issue to Avant 1 million shares of its common stock, and Avant will issue to Amarantus an additional 32 million shares of its common stock as a repayment of debt.

Amarantus said it plans to assign the diagnostic assets to a new subsidiary.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.